Does your child have myopia? If they’re nearsighted, CooperVision may have a solution to slow down the progression of this all-too-common eye issue.
The vision company recently announced the U.S. Food and Drug Administration approval of its MiSight 1 day contact lens. Unlike other lenses, this daily wear, single-use contact product is shown to slow the development of myopia when prescribed for children ages 8 through 12.
photo: Pexen Designs via Pexels
In a press statement, Daniel G. McBride, President of CooperVision, said, “We can’t overstate the importance and potential impact of this landmark decision on children’s vision, especially considering the rise in myopia’s severity and prevalence in the U.S. and worldwide.” McBride continued, “Eye care professionals who embrace this breakthrough approach will improve the quality of life and eye health for so many children.”
Michele Andrews, OD, Senior Director of North America Professional and Academic Affairs for CooperVision, added, “While there is growing acknowledgment and interest in stemming myopia’s progression, there needs to be more urgency to act earlier. We believe that MiSight 1 day will be a catalyst that helps ECPs move faster and gives rise to better ECP-parent conversations about the issue. It’s a privilege to be at the forefront of myopia management.”
The recent FDA approval follows a multi-year study of children ages 8 through 12 from Singapore, Canada, Portugal and the United Kingdom. The results, which were published in the journal Optometry and Vision Sciences, showed that the lenses slowed the progression by over 50 percent.
The contact lenses, which are already prescribed in Canada, the United Kingdom, Australia and Spain, will launch in the United States in March of 2020.